Renaissance Technologies
IMPL

Renaissance Technologies’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Renaissance Technologies’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,300
Closed -$17K – 4379
2023
Q1 		$17K Sell
12,300
-3,100
-20% -$7.4K ﹤0.01% 3847
2022
Q4 		$58K Sell
15,400
-2,000
-11% -$7.29K ﹤0.01% 3772
2022
Q3 		$85K Buy
17,400
+200
+1% +$1.53K ﹤0.01% 3645
2022
Q2 		$160K Sell
17,200
-16,000
-48% -$117K ﹤0.01% 3730
2022
Q1 		$211K Buy
+33,200
New +$251K ﹤0.01% 3630

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies's IMPL Position: Q2 2023 in Review

Renaissance Technologies sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q2 2023, closing a stake of 12,300 shares — an estimated $17K sold.

Renaissance Technologies first reported a position in IMPL in Q1 2022 and held it in 5 quarters. The position peaked at $211K in Q1 2022. 32 funds tracked by Wall St. Rank hold IMPL as of Q2 2023.

  • Renaissance Technologies reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Renaissance Technologies sold 12,300 Impel Pharmaceuticals Inc. Common Stock shares in Q2 2023, an estimated $17K.
  • Renaissance Technologies first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q1 2022 and held it in 5 quarters.
  • Renaissance Technologies's Impel Pharmaceuticals Inc. Common Stock position peaked at $211K in Q1 2022.
  • 32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.